100% de satisfacción garantizada Inmediatamente disponible después del pago Tanto en línea como en PDF No estas atado a nada 4.2 TrustPilot
logo-home
Examen

CSOWM EXAM PREP QUESTIONS WITH CORRECT ANSWERS

Puntuación
-
Vendido
-
Páginas
52
Grado
A+
Subido en
12-01-2026
Escrito en
2025/2026

CSOWM EXAM PREP QUESTIONS WITH CORRECT ANSWERS

Institución
CSO,CSOWM
Grado
CSO,CSOWM











Ups! No podemos cargar tu documento ahora. Inténtalo de nuevo o contacta con soporte.

Escuela, estudio y materia

Institución
CSO,CSOWM
Grado
CSO,CSOWM

Información del documento

Subido en
12 de enero de 2026
Número de páginas
52
Escrito en
2025/2026
Tipo
Examen
Contiene
Preguntas y respuestas

Temas

Vista previa del contenido

CSOWM EXAM PREPQUESTIONSWITH v v v v




CORRECT ANSWERS 2025 v v v




Physical Activity for Children/Adolescents with DM (1 & 2) & Pre-DM - CORRECT ANSWER -
v v v v v v v v v v v v v v




At least 60 min/day of moderate to vigorous aerobic activity
v v v v v v v v v




vigorous muscle strengthening and bone strengthening activity at least 3 days per week
v v v v v v v v v v v v




Physical Activity for Adults with DM - CORRECT ANSWER -
v v v v v v v v v




150 min of moderate to vigorous aerobic activity weekly (over at least 3 days)
v v v v v v v v v v v v v




no more than 2 consecutive days w/o activity
v v v v v v v




75 min of vigorous aerobic activity weekly (if appropriate)
v v v v v v v v




2-3 weekly sessions of resistance exercise on non consecutive days
v v v v v v v v v




all adults should decrease sedentary time (interrupt every 30 min for BG benefit)
v v v v v v v v v v v v




flexibility & balance training recommended 2-3 times weekly for older adults with DM
v v v v v v v v v v v v




Potential contraindications for diabetes and exercise - CORRECT ANSWER -
v v v v v v v v v




Retinopathy (risk of vitreous hemorrhage or retinal detachment)
v v v v v v v v




Peripheral neuropathy (exam feet, wear protection)
v v v v v




Autonomic neuropathy (thorough cardiac eval) v v v v




Diabetic kidney disease (acutely increase urinate albumin excretion) , however no specific exercise rest
v v v v v v v v v v v v v




rictions needed.
v v

,DM and Psychosocial Care - CORRECT ANSWER -Should be integrated with a pt-
v v v v v v v v v v v v




centered approach & provided to all people diagnosed
v v v v v v v v




may include attitudes: expectations with meds and outcomes, affect or mood, QOL, resources like fina
v v v v v v v v v v v v v v




ncial, social, emotional, and psychiatric history
v v v v v v




Critical times to evaluate DSMES - CORRECT ANSWER -1. At diagnosis
v v v v v v v v v v




2. Annually

3. When complications arise v v




4. When transitions in care occur v v v v




Behavior Management for Diabetics - CORRECT ANSWER -DSMES
v v v v v v v




v MNT

Physical Activity v




Smoking cessation v




v Psychosocial care v




Pharmacotherapy for type 2 DM - CORRECT ANSWER -Metformin initially (low cost) v v v v v v v v v v v




Early insulin if evidence of catabolism, hyperglycemia, & A1c > 10%
v v v v v v v v v v




SGLT-2 inhibitors or GLP-1 agonist in patients with CVD, kidney dx, or heart failure
v v v v v v v v v v v v v




DPP-4 inhibitors - CORRECT ANSWER -weight neutral type II DM medication ends
v v v v v v v v v v v




v in -gliptin
v




(Januvia)

Better GI tolerability over Metformin
v v v v




Type II DM Meds that cause weight gain - CORRECT ANSWER -Thiazolidinediones (low cost)
v v v v v v v v v v v v v

,Sulfonylureas (Glyburide, Glipizide, Glimepiride) (low cost) v v v v v




v Insulin



GLP-1 Agonists - CORRECT ANSWER -Liraglutide (Victoza, Saxenda)
v v v v v v v




v Semaglutide (Ozempic, Wegovy) v v




Exenatide
Dulaglutide (Trulicity) v




Injections that affect POMC neurons and cause satiety v v v v v v v




SGLT2 inhibitors - CORRECT ANSWER -Canagliflozin (Invokana)
v v v v v v




v Dapagliflozin (Farxiga) v




Empagliflozin (Jardiance) v




prevents reabsorptions of glucose as well as water in the renal tubules
v v v v v v v v v v v




Assessment of Obesity Management in Type II DM - CORRECT ANSWER - v v v v v v v v v v v




Annual BMI calculations (more frequently if necessary)
v v v v v v v




Inpatient eval may be necessary if deterioration of medical status is associated with significant weight gain
v v v v v v v v v v v v v v v




or loss (medication use, food intake, glycemic status)
v v v v v v v v




For pt's with high weight-related stress, special accommodations should be made to ensure privacy
v v v v v v v v v v v v v




Obesity Management in Type II DM (short-term) - CORRECT ANSWER -
v v v v v v v v v v




Diet, PA, and BT designed to achieve and maintain >/= 5% weight loss (3- 5%
v v v v v v v v v v v v v v




is minimum for any benefit)
v v v v v




>/= 16 sessions in 6 months
v v v v v




Achieve a 500-750 kcal deficit (individualized meal planning)
v v v v v v v

, Individual or group settings v v v




Very low-calorie diets (</= 800 kcal) prescribed only to carefully selected patients
v v v v v v v v v v v




Obesity Management in Type II DM (long-term) - CORRECT ANSWER - For
v v v v v v v v v v v




>/= 1 year weight maintenance:
v v v v v




- minimum monthly contact v v




- 200-300 min/wk of physical activity v v v v




-self-monitoring



Look AHEAD Trial - CORRECT ANSWER -Assessed long-
v v v v v v v




term health consequences of intentional wt loss. Showed feasibility of achievingGand maintaining long-
v v v v v v v v v v v v




term (13.5 years) weight loss in patients with type II DM.
v v v v v v v v v v v




Participants randomly assigned to the intensive lifestyle group achieved equivalent risk factor control b ut
v v v v v v v v v v v v v v




required fewer glucose-, blood pressure-, and lipid-
v v v v v v v




lowering meds than those randomly assigned to standard care. Other improvements included increase d
v v v v v v v v v v v v v




mobility, physical and sexual functioning, and health-related QoL
v v v v v v v v




(did NOT show reduced CVD events in diabetics & overweight/obesity)
v v v v v v v v v




DM meds that can promote weight loss - CORRECT ANSWER -Metformin
v v v v v v v v v v




v Alpha-glucosidase inhibitors v




SGLT-2 inhibitors v




GLP-1 agonsits
v v




Amylin mimetics (Pramlintide) v v




Metabolic Surgery for Type II DM - CORRECT ANSWER -BMI >/= 35 (Asian Americans >/= 32.5)
v v v v v v v v v v v v v v v




Pts who do not achieve durable weight loss and improvement in comorbidities with nonsurgical metho ds
v v v v v v v v v v v v v v v
$12.99
Accede al documento completo:

100% de satisfacción garantizada
Inmediatamente disponible después del pago
Tanto en línea como en PDF
No estas atado a nada

Conoce al vendedor
Seller avatar
NurseStudyGuides

Conoce al vendedor

Seller avatar
NurseStudyGuides Howard Community College
Seguir Necesitas iniciar sesión para seguir a otros usuarios o asignaturas
Vendido
0
Miembro desde
6 meses
Número de seguidores
0
Documentos
533
Última venta
-

0.0

0 reseñas

5
0
4
0
3
0
2
0
1
0

Recientemente visto por ti

Por qué los estudiantes eligen Stuvia

Creado por compañeros estudiantes, verificado por reseñas

Calidad en la que puedes confiar: escrito por estudiantes que aprobaron y evaluado por otros que han usado estos resúmenes.

¿No estás satisfecho? Elige otro documento

¡No te preocupes! Puedes elegir directamente otro documento que se ajuste mejor a lo que buscas.

Paga como quieras, empieza a estudiar al instante

Sin suscripción, sin compromisos. Paga como estés acostumbrado con tarjeta de crédito y descarga tu documento PDF inmediatamente.

Student with book image

“Comprado, descargado y aprobado. Así de fácil puede ser.”

Alisha Student

Preguntas frecuentes